RxDoctor Payments Data

Sarah Chisolm, MD

Dermatology · Atlanta, GANPI 1255592127

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $56,326 of the $59,373 with a category attached, or 94.9%. 12 manufacturers reported payments, led by Sanofi at 34.3% of the total. Among dermatology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$59,373in general payments, 2019–2025

Across 44 payments — averaging $1349.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$20K
  • Novartis$12K
  • Vifor Pharma, Inc.$9K
  • Incyte Corporation$7K
  • Regeneron Healthcare Solutions, Inc.$4K
  • Galderma Laboratories, L.p.$3K
  • plus $4K from 6 others
$74,924in research payments, 2019–2025

Across 15 payments — averaging $4994.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$39K
  • Pfizer$36K
  • Incyte Corporation$45

What the payments were for

  • Consulting fees$56,32695%
  • Travel & lodging$1,9163%
  • Food & beverage$1,1312%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$59,373 in reported general payments places this provider in the 95th percentile of 345 dermatology providers in Georgia.

See all dermatology providers in Georgia

Medicare billing

Part B allowed, 2024
$3,784
Medicare patients
71
Services billed
85

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →